Jeonjinbio Past Earnings Performance
Past criteria checks 0/6
Jeonjinbio's earnings have been declining at an average annual rate of -10.9%, while the Chemicals industry saw earnings growing at 6.8% annually. Revenues have been growing at an average rate of 41.2% per year.
Key information
-10.9%
Earnings growth rate
0.8%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | 41.2% |
| Return on equity | -1.2% |
| Net Margin | -1.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On Capital
Oct 25
With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay For
Jun 07Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price
Apr 03Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?
Apr 13If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% Returns
Feb 19
Revenue & Expenses Breakdown
How Jeonjinbio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 19,142 | -201 | 3,792 | 430 |
| 31 Mar 24 | 17,686 | -5,550 | 3,841 | 455 |
| 31 Dec 23 | 15,681 | -6,440 | 3,937 | 448 |
| 30 Sep 23 | 13,204 | -4,308 | 3,914 | 419 |
| 30 Jun 23 | 10,893 | -4,905 | 3,753 | 425 |
| 31 Mar 23 | 9,055 | -2,999 | 3,560 | 405 |
| 31 Dec 22 | 7,794 | -3,113 | 3,373 | 422 |
| 30 Sep 22 | 5,899 | -2,504 | 3,384 | 399 |
| 30 Jun 22 | 4,557 | -2,228 | 3,374 | 371 |
| 31 Mar 22 | 3,457 | -2,462 | 3,328 | 411 |
| 31 Dec 21 | 3,214 | -2,108 | 3,716 | 364 |
| 30 Sep 21 | 3,496 | -3,609 | 3,793 | 375 |
| 30 Jun 21 | 3,796 | -3,275 | 3,698 | 352 |
| 31 Mar 21 | 3,910 | -3,882 | 3,794 | 346 |
| 31 Dec 20 | 3,867 | -3,418 | 3,400 | 345 |
| 30 Sep 20 | 4,732 | -1,604 | 3,677 | 353 |
| 30 Jun 20 | 4,643 | -1,648 | 3,756 | 447 |
| 31 Mar 20 | 4,426 | -1,330 | 3,532 | 416 |
| 31 Dec 19 | 3,949 | -1,462 | 3,194 | 465 |
| 30 Sep 19 | 2,230 | -3,437 | 3,008 | 532 |
| 30 Jun 19 | 1,357 | -3,579 | 2,587 | 458 |
| 31 Mar 19 | 1,243 | -3,495 | 2,452 | 428 |
| 31 Dec 18 | 1,384 | -3,399 | 2,502 | 361 |
| 30 Sep 18 | 2,216 | -3,610 | 3,325 | 258 |
| 30 Jun 18 | 2,392 | -3,366 | 3,287 | 219 |
| 31 Mar 18 | 2,792 | -3,130 | 3,302 | 209 |
| 31 Dec 17 | 3,136 | -3,041 | 3,442 | 192 |
| 30 Sep 17 | 2,645 | -2,626 | 2,698 | 183 |
| 30 Jun 17 | 3,106 | -3,325 | 3,491 | 198 |
| 31 Mar 17 | 2,895 | -3,697 | 3,461 | 233 |
| 31 Dec 16 | 4,809 | -3,074 | 4,439 | 196 |
| 31 Dec 15 | 2,018 | -2,931 | 2,597 | 37 |
| 31 Dec 14 | 13,727 | -389 | 1,790 | 0 |
| 31 Dec 13 | 17,603 | -1,694 | 1,654 | 0 |
Quality Earnings: A110020 is currently unprofitable.
Growing Profit Margin: A110020 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A110020 is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare A110020's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A110020 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (21.4%).
Return on Equity
High ROE: A110020 has a negative Return on Equity (-1.19%), as it is currently unprofitable.